Published in Biochem J on August 01, 2001
Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc Natl Acad Sci U S A (2010) 1.20
Pulmonary delivery of an aerosolized recombinant human butyrylcholinesterase pretreatment protects against aerosolized paraoxon in macaques. Chem Biol Interact (2012) 0.84
Amino acid domains control the circulatory residence time of primate acetylcholinesterases in rhesus macaques (Macaca mulatta). Biochem J (2004) 0.79
Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. Biochem Pharmacol (2010) 0.79
Overloading and removal of N-glycosylation targets on human acetylcholinesterase: effects on glycan composition and circulatory residence time. Biochem J (2002) 0.78
Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples. Br J Pharmacol (2010) 0.75
Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger. Ann N Y Acad Sci (2016) 0.75
A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol (1961) 45.34
Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem (1977) 2.50
Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol (1999) 2.02
Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med (1987) 1.75
Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G + C-rich attenuating structure. Proc Natl Acad Sci U S A (1990) 1.50
Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem (1995) 1.48
Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr (2000) 1.47
Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center. EMBO J (1992) 1.43
Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem J (1996) 1.41
Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry (1995) 1.31
Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit. Gene (1992) 1.28
Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem (1992) 1.25
Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem (1988) 1.22
Site of fasciculin interaction with acetylcholinesterase. J Biol Chem (1994) 1.19
Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem (1996) 1.19
Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol Pharmacol (1998) 1.17
Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem (1994) 1.14
The effect of elimination of intersubunit disulfide bonds on the activity, assembly, and secretion of recombinant human acetylcholinesterase. Expression of acetylcholinesterase Cys-580----Ala mutant. J Biol Chem (1991) 1.10
Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem J (1998) 1.00
The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors. J Biol Chem (1996) 1.00
Chemical modification of enzymes for enhanced functionality. Curr Opin Biotechnol (1999) 1.00
Asp7O in the peripheral anionic site of human butyrylcholinesterase. Eur J Biochem (1996) 1.00
Aspartate 74 as a primary determinant in acetylcholinesterase governing specificity to cationic organophosphonates. Biochemistry (1996) 1.00
Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Biochemistry (1997) 1.00
Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation. Biochem J (1995) 0.99
Stabilization of substances in circulation. Bioconjug Chem (1998) 0.99
Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res (1997) 0.97
Conserved aromatic residues of the C-terminus of human butyrylcholinesterase mediate the association of tetramers. Biochemistry (1999) 0.95
Evaluation of anchorage-dependent cell propagation systems for production of human acetylcholinesterase by recombinant 293 cells. Cytotechnology (1993) 0.95
PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol (1998) 0.94
Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol (1981) 0.93
Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam Appl Toxicol (1987) 0.92
Effect of human acetylcholinesterase subunit assembly on its circulatory residence. Biochem J (2001) 0.90
Expression and reconstitution of biologically active human acetylcholinesterase from Escherichia coli. Cell Mol Neurobiol (1993) 0.90
Methodology for pharmacokinetic/pharmacodynamic data analysis. Pharm Sci Technolo Today (1999) 0.88
Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase. Pharmacol Res Commun (1982) 0.88
Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther (1981) 0.87
Bovine acetylcholinesterase: cloning, expression and characterization. Biochem J (1998) 0.85
Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase. Toxicol Appl Pharmacol (1992) 0.83
Applications of site-specific chemical modification in the manufacture of biopharmaceuticals: I. An overview. Biotechnol Appl Biochem (1997) 0.82
Oxidative stress-induced activation of microsomal glutathione S-transferase in isolated rat liver. Biochem Pharmacol (1993) 0.81
Mouse beta 2-microglobulin cDNA clones: a screening procedure for cDNA clones corresponding to rare mRNAs. Proc Natl Acad Sci U S A (1981) 6.67
Essential virulence determinants of different Yersinia species are carried on a common plasmid. Plasmid (1981) 4.07
Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun (2001) 2.67
Plasmid R6K DNA replication. III. Regulatory properties of the pi initiation protein. J Mol Biol (1982) 2.12
Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun (2000) 1.93
Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. J Biol Chem (1993) 1.72
Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry (1999) 1.55
Conditional expression of the vesicular stomatitis virus glycoprotein gene in Escherichia coli. Proc Natl Acad Sci U S A (1981) 1.53
Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr (2000) 1.47
Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center. EMBO J (1992) 1.43
Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem J (1996) 1.41
Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine (1993) 1.32
Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit. Gene (1992) 1.28
Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect Immun (2002) 1.26
Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem (1992) 1.25
Structural properties of the beta origin of replication of plasmid R6K. J Biol Chem (1983) 1.22
Evidence for P-N bond scission in phosphoroamidate nerve agent adducts of human acetylcholinesterase. Biochemistry (2000) 1.21
N-glycosylation of human acetylcholinesterase: effects on activity, stability and biosynthesis. Biochem J (1993) 1.20
Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem (1994) 1.14
Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun (2003) 1.11
The effect of elimination of intersubunit disulfide bonds on the activity, assembly, and secretion of recombinant human acetylcholinesterase. Expression of acetylcholinesterase Cys-580----Ala mutant. J Biol Chem (1991) 1.10
ColE1 DNA sequences interacting in cis, essential for mitomycin-C induced lethality. Mol Gen Genet (1979) 1.08
Exploring the active center of human acetylcholinesterase with stereomers of an organophosphorus inhibitor with two chiral centers. Biochemistry (1999) 1.05
Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. J Virol (1989) 1.04
Engineering resistance to 'aging' of phosphylated human acetylcholinesterase. Role of hydrogen bond network in the active center. FEBS Lett (1993) 1.04
Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase. J Biol Chem (1995) 1.03
Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem J (1998) 1.00
Interrelations between assembly and secretion of recombinant human acetylcholinesterase. J Biol Chem (1993) 1.00
Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines. Infect Immun (2003) 1.00
The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors. J Biol Chem (1996) 1.00
Allosteric modulation of acetylcholinesterase activity by peripheral ligands involves a conformational transition of the anionic subsite. Biochemistry (1995) 1.00
Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation. Biochem J (1995) 0.99
The "back door" hypothesis for product clearance in acetylcholinesterase challenged by site-directed mutagenesis. J Biol Chem (1994) 0.99
Recombinant human acetylcholinesterase is secreted from transiently transfected 293 cells as a soluble globular enzyme. Cell Mol Neurobiol (1991) 0.96
Electrostatic attraction by surface charge does not contribute to the catalytic efficiency of acetylcholinesterase. EMBO J (1994) 0.95
Evaluation of anchorage-dependent cell propagation systems for production of human acetylcholinesterase by recombinant 293 cells. Cytotechnology (1993) 0.95
Resolving pathways of interaction of covalent inhibitors with the active site of acetylcholinesterases: MALDI-TOF/MS analysis of various nerve agent phosphyl adducts. Chem Res Toxicol (2001) 0.94
Cleavage maps of a tetracycline plasmid from Staphylococcus aureus. J Bacteriol (1978) 0.94
Identification and characterization of the functional alpha origin of DNA replication of the R6K plasmid and its relatedness to the R6K beta and gamma origins. Mol Gen Genet (1987) 0.94
Functional characteristics of the oxyanion hole in human acetylcholinesterase. J Biol Chem (1998) 0.93
Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun (2005) 0.93